Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
It is the first monoclonal antibody drug for use in any animal species
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The last date to apply for this program is 18th January 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Subscribe To Our Newsletter & Stay Updated
